Developer docs
API playgroundTry for free, no card

Search company profiles

Alligator Bioscience

Full company profile

uuid0000tu6

Namestring
Alligator Bioscience
Legal namestring
Alligator Bioscience AB
Company typeenum
Public
Founded yearint
1997
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-based immunotherapies, cancer immunotherapy development, bispecific antibody platforms, immuno-oncology therapeutics, clinical-stage biopharmaceuticals
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alligator Bioscience is a clinical-stage biotechnology company developing antibody-based immunotherapies for cancer treatment. Its portfolio centers on tumor-directed mono- and bispecific antibodies targeting the CD40 receptor and other immune pathways, including the lead candidate mitazalimab (a CD40 agonist for pancreatic cancer), the bispecific ATOR-4066 (CD40xCEACAM5), ALG.APV-527 (4-1BBx5T4), and ATOR-1017 (4-1BB agonist). The company also licenses the anti-HER2 antibody HLX22 via Shanghai Henlius, and offers proprietary bispecific platforms Neo-X-Prime and RUBY for partnership-based development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 87% clinical benefit rate and 81% remission rate in acute myeloid leukemia patients
+1 more record
Product overview1 text field

Alligator Bioscience is a clinical-stage Swedish biotechnology company developing tumor-directed immuno-oncology antibody drugs. The company's portfolio consists of agonistic monoclonal and bispecific antibodies targeting the CD40 receptor and other immune pathways for cancer treatment. The core pipeline includes: Mitazalimab (lead CD40 agonist antibody in Phase 3 preparation for pancreatic cancer), ATOR-4066 (CD40×CEACAM5 bispecific using Neo-X-Prime™ platform), ALG.APV-527 (4-1BB×5T4 bispecific co-developed with Aptevo), and ATOR-1017 (4-1BB agonist). Additionally, HLX22 (anti-HER2 antibody) is licensed to Henlius with Alligator receiving revenue shares. The company also offers its proprietary RUBY™ bispecific antibody platform for partnerships.

Product and service6 records
1Mitazalimab
CategoryOncology therapeutic antibody
Description

Tumor-directed CD40 agonist monoclonal antibody in clinical development (Phase 3 preparation) for metastatic pancreatic cancer in combination with mFOLFIRINOX chemotherapy. Targets oncology patients with limited treatment options.

2ATOR-4066 (Neo-X-Prime)
CategoryOncology bispecific antibody
Description

Bispecific antibody built on the proprietary Neo-X-Prime format, targeting CD40 and CEACAM5 antigens, intended for next-generation immunotherapies in multiple oncology indications.

3ALG.APV-527
CategoryOncology bispecific antibody
Description

First-in-class bispecific antibody co-developed with Aptevo Therapeutics, targeting 4-1BB and 5T4 tumor antigen for immune activation in solid tumors; Phase 1 reported 60% of evaluable patients with stable disease.

4ATOR-1017 (evunzekibart)
CategoryOncology agonist antibody
Description

4-1BB (CD137) agonist monoclonal antibody designed for immune activation in patients with advanced solid malignancies.

5HLX22 (AC101)
CategoryLicensed oncology antibody
Description

Anti-HER2 monoclonal antibody originally developed by AbClon, sublicensed to Shanghai Henlius Biotech; in Phase 2/3 for HER2-positive breast cancer and Phase 3 for gastric cancer. Alligator is entitled to 35% of AbClon's revenue from the Henlius sublicense.

6RUBY Bispecific Antibody Platform
CategoryBispecific antibody technology platform
Description

Proprietary tetravalent bispecific antibody format enabling stable assembly of bispecific antibodies with dual antigen binding capability, offered through evaluation/option agreements to partners for next-generation immunotherapy development.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1RUBY Antibody Format Partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-02
Description

Evaluation and option agreement covering RUBY antibody format signed in September 2025, supporting company's strategy to build long-term value through partnerships.

pharmiweb.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-04-27
Description

Collaboration on REACtiVe-2 Phase 1 study combining mitazalimab with Amphera's MesoPher cell therapy in pancreatic cancer. Both companies announced last patient treated in the study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-13
Description

Co-development partnership for ALG.APV-527, a bispecific antibody targeting 5T4 tumor antigen. Companies presented positive Phase 1 data showing 60% of evaluable patients achieved stable disease. Jointly advancing clinical development for solid tumor cancers.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-19
Description

Sponsored research agreement led by Dr. Gregory Beatty for preclinical and clinical research on mitazalimab and related immunotherapies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-08
Description

Investigator-initiated Phase 1 clinical trial of mitazalimab conducted at Erasmus Medical Center.

6Shanghai Henlius Biotech
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-21
Description

Partnership for development of HLX22 (also known as AC101), an anti-HER2 monoclonal antibody. Henlius is conducting Phase 2/3 trials in breast cancer and Phase 3 in gastric cancer. Alligator is entitled to 35% of AbClon's revenue from sublicense agreements with Henlius.

alligatorbioscience.se
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-09-02
Description

Collaboration on preclinical data supporting efficacy of mitazalimab in combination therapy with Scandion's lead compound.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-18
Description

Immuno-oncology Research Collaboration and License Agreement signed in August 2021 for the development of novel immuno-oncology drugs. Orion exercised development options under the agreement, and Alligator received milestone payments. Collaboration includes multiple programs with Orion taking responsibility for future development and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-18
Description

Original developer of HLX22/AC101 antibody. Alligator holds rights to the molecule and sublicenses to partners like Henlius. Receives 35% of AbClon's revenue from sublicense agreements.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-05-04
Description

Research agreement in the neurodegenerative field, exploring potential applications of antibody technology beyond oncology.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-04-15
Description

Research collaboration to develop a novel immunotherapy combining双方的抗体技术平台。

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct co-development partner on ALG.APV-527 (4-1BBx5T4 bispecific) and a clinical-stage immuno-oncology company building bispecific antibody candidates with a comparable technology profile to Alligator's pipeline.

TypeDirect peer
Description

Clinical-stage oncology company with proprietary bispecific antibody platforms (DART, TRIDENT) and a pipeline of immuno-oncology antibodies, including 4-1BB and HER2-targeted assets directly comparable to Alligator's bispecific strategy. Alligator has a research collaboration with MacroGenics.

TypeDirect peer
Description

Pioneer in bispecific antibody technology (DuoBody, HexaBody) with a broad clinical-stage oncology pipeline; competes in the same bispecific antibody modality space as Alligator's RUBY and Neo-X-Prime platforms.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) that activate myeloid and antigen-presenting cells via agonist antibodies — closely analogous mechanism to Alligator's CD40 agonist strategy.

TypeEmerging player
Description

Clinical-stage company developing INDUKINE™ conditionally activated immune agonists for oncology, targeting the same space of tumor-directed immune activation as Alligator's CD40 agonist pipeline.

TypeEmerging player
Description

Clinical-stage oncology company with a Probody® masked antibody platform for tumor-selective activation, offering an alternative approach to tumor-directed antibody therapeutics comparable to Alligator's tumor-directed CD40 design.

TypeEmerging player
Description

Computational immuno-oncology company with clinical-stage antibody programs targeting novel immune checkpoints, representing a comparable clinical-stage IO platform player with similar size and stage.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company with a comparable size and oncology/rare disease pipeline profile, sharing similar late-clinical-stage small-cap dynamics and partnering-driven business model.

TypeBroad incumbent
Description

Global oncology leader with multiple CD20/CD40 agonist programs (e.g., mitazalimab-like CD40 agonist efforts) and a broad bispecific antibody franchise, serving as the dominant large-pharma competitor in Alligator's target space.

TypeBroad incumbent
Description

Major oncology incumbent with extensive immuno-oncology, bispecific antibody (e.g., bispecific T-cell engagers) and CD40 agonist programs, representing a large-pharma benchmark for Alligator's immuno-oncology strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alligator Bioscience

Cancer Immunotherapyalligatorbioscience.se

Alligator Bioscience firmographics

Firmographics
Name
Alligator Bioscience
Legal name
Alligator Bioscience AB
Website
https://alligatorbioscience.se
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Alligator Bioscience industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody-based immunotherapies
  • Cancer immunotherapy development
  • Bispecific antibody platforms
  • Immuno-oncology therapeutics
  • Clinical-stage biopharmaceuticals

Where Alligator Bioscience is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Alligator Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels3 records

Alligator Bioscience product offering

Product offering

Core offering

Alligator Bioscience is a clinical-stage biotechnology company developing antibody-based immunotherapies for cancer treatment. Its portfolio centers on tumor-directed mono- and bispecific antibodies targeting the CD40 receptor and other immune pathways, including the lead candidate mitazalimab (a CD40 agonist for pancreatic cancer), the bispecific ATOR-4066 (CD40xCEACAM5), ALG.APV-527 (4-1BBx5T4), and ATOR-1017 (4-1BB agonist). The company also licenses the anti-HER2 antibody HLX22 via Shanghai Henlius, and offers proprietary bispecific platforms Neo-X-Prime and RUBY for partnership-based development.

Product overview

Alligator Bioscience is a clinical-stage Swedish biotechnology company developing tumor-directed immuno-oncology antibody drugs. The company's portfolio consists of agonistic monoclonal and bispecific antibodies targeting the CD40 receptor and other immune pathways for cancer treatment. The core pipeline includes: Mitazalimab (lead CD40 agonist antibody in Phase 3 preparation for pancreatic cancer), ATOR-4066 (CD40×CEACAM5 bispecific using Neo-X-Prime™ platform), ALG.APV-527 (4-1BB×5T4 bispecific co-developed with Aptevo), and ATOR-1017 (4-1BB agonist). Additionally, HLX22 (anti-HER2 antibody) is licensed to Henlius with Alligator receiving revenue shares. The company also offers its proprietary RUBY™ bispecific antibody platform for partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mitazalimab Tumor-directed CD40 agonist monoclonal antibody in clinical development (Phase 3 preparation) for metastatic pancreatic cancer in combination with mFOLFIRINOX chemotherapy. Targets oncology patients with limited treatment options.
  • ATOR-4066 (Neo-X-Prime) Bispecific antibody built on the proprietary Neo-X-Prime format, targeting CD40 and CEACAM5 antigens, intended for next-generation immunotherapies in multiple oncology indications.
  • ALG.APV-527 First-in-class bispecific antibody co-developed with Aptevo Therapeutics, targeting 4-1BB and 5T4 tumor antigen for immune activation in solid tumors; Phase 1 reported 60% of evaluable patients with stable disease.
  • ATOR-1017 (evunzekibart) 4-1BB (CD137) agonist monoclonal antibody designed for immune activation in patients with advanced solid malignancies.
  • HLX22 (AC101) Anti-HER2 monoclonal antibody originally developed by AbClon, sublicensed to Shanghai Henlius Biotech; in Phase 2/3 for HER2-positive breast cancer and Phase 3 for gastric cancer. Alligator is entitled to 35% of AbClon's revenue from the Henlius sublicense.
  • RUBY Bispecific Antibody Platform Proprietary tetravalent bispecific antibody format enabling stable assembly of bispecific antibodies with dual antigen binding capability, offered through evaluation/option agreements to partners for next-generation immunotherapy development.

Quantifiable outcome

  • 87% clinical benefit rate and 81% remission rate in acute myeloid leukemia patients
  • +1 more outcomes

Companies that use Alligator Bioscience

Customer profile

Segments1 record

Ideal customer profiles2 records

Alligator Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Alligator Bioscience partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered minor and core.

  • RUBY Antibody Format PartnerminorStrategic or Co-development Partner · 2 September 2025Evaluation and option agreement covering RUBY antibody format signed in September 2025, supporting company's strategy to build long-term value through partnerships.
  • AmpheraminorStrategic or Co-development Partner · 27 April 2023Collaboration on REACtiVe-2 Phase 1 study combining mitazalimab with Amphera's MesoPher cell therapy in pancreatic cancer. Both companies announced last patient treated in the study.
  • Aptevo TherapeuticscoreStrategic or Co-development Partner · 13 February 2023Co-development partnership for ALG.APV-527, a bispecific antibody targeting 5T4 tumor antigen. Companies presented positive Phase 1 data showing 60% of evaluable patients achieved stable disease. Jointly advancing clinical development for solid tumor cancers.
  • University of PennsylvaniaminorStrategic or Co-development Partner · 19 January 2022Sponsored research agreement led by Dr. Gregory Beatty for preclinical and clinical research on mitazalimab and related immunotherapies.
  • Erasmus University RotterdamminorStrategic or Co-development Partner · 8 November 2021Investigator-initiated Phase 1 clinical trial of mitazalimab conducted at Erasmus Medical Center.
  • Shanghai Henlius BiotechcoreStrategic or Co-development Partner · 21 October 2021Partnership for development of HLX22 (also known as AC101), an anti-HER2 monoclonal antibody. Henlius is conducting Phase 2/3 trials in breast cancer and Phase 3 in gastric cancer. Alligator is entitled to 35% of AbClon's revenue from sublicense agreements with Henlius.
  • Scandion OncologyminorStrategic or Co-development Partner · 2 September 2021Collaboration on preclinical data supporting efficacy of mitazalimab in combination therapy with Scandion's lead compound.
  • Orion CorporationcoreStrategic or Co-development Partner · 18 August 2021Immuno-oncology Research Collaboration and License Agreement signed in August 2021 for the development of novel immuno-oncology drugs. Orion exercised development options under the agreement, and Alligator received milestone payments. Collaboration includes multiple programs with Orion taking responsibility for future development and commercialization.
  • AbCloncoreStrategic or Co-development Partner · 18 August 2021Original developer of HLX22/AC101 antibody. Alligator holds rights to the molecule and sublicenses to partners like Henlius. Receives 35% of AbClon's revenue from sublicense agreements.
  • BioArcticminorStrategic or Co-development Partner · 4 May 2021Research agreement in the neurodegenerative field, exploring potential applications of antibody technology beyond oncology.
  • MacroGenicsminorStrategic or Co-development Partner · 15 April 2021Research collaboration to develop a novel immunotherapy combining双方的抗体技术平台。

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Alligator Bioscience competitors and assessment

Company assessment

Direct peers

  • Aptevo Therapeutics: Direct co-development partner on ALG.APV-527 (4-1BBx5T4 bispecific) and a clinical-stage immuno-oncology company building bispecific antibody candidates with a comparable technology profile to Alligator's pipeline.
  • MacroGenics: Clinical-stage oncology company with proprietary bispecific antibody platforms (DART, TRIDENT) and a pipeline of immuno-oncology antibodies, including 4-1BB and HER2-targeted assets directly comparable to Alligator's bispecific strategy. Alligator has a research collaboration with MacroGenics.
  • Genmab: Pioneer in bispecific antibody technology (DuoBody, HexaBody) with a broad clinical-stage oncology pipeline; competes in the same bispecific antibody modality space as Alligator's RUBY and Neo-X-Prime platforms.

Emerging players

  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) that activate myeloid and antigen-presenting cells via agonist antibodies — closely analogous mechanism to Alligator's CD40 agonist strategy.
  • Werewolf Therapeutics: Clinical-stage company developing INDUKINE™ conditionally activated immune agonists for oncology, targeting the same space of tumor-directed immune activation as Alligator's CD40 agonist pipeline.
  • CytomX Therapeutics: Clinical-stage oncology company with a Probody® masked antibody platform for tumor-selective activation, offering an alternative approach to tumor-directed antibody therapeutics comparable to Alligator's tumor-directed CD40 design.
  • Compugen: Computational immuno-oncology company with clinical-stage antibody programs targeting novel immune checkpoints, representing a comparable clinical-stage IO platform player with similar size and stage.
  • Mereo BioPharma: Clinical-stage biopharmaceutical company with a comparable size and oncology/rare disease pipeline profile, sharing similar late-clinical-stage small-cap dynamics and partnering-driven business model.

Broad incumbents

  • Roche: Global oncology leader with multiple CD20/CD40 agonist programs (e.g., mitazalimab-like CD40 agonist efforts) and a broad bispecific antibody franchise, serving as the dominant large-pharma competitor in Alligator's target space.
  • AstraZeneca: Major oncology incumbent with extensive immuno-oncology, bispecific antibody (e.g., bispecific T-cell engagers) and CD40 agonist programs, representing a large-pharma benchmark for Alligator's immuno-oncology strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Alligator Bioscience social profiles

Digital presence

Alligator Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alligator Bioscience leadership team

Management profile

Number of profiles

Profiles6 records

Alligator Bioscience funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alligator Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alligator Bioscience

What does Alligator Bioscience do?

Alligator Bioscience is a clinical-stage biotechnology company developing antibody-based immunotherapies for cancer treatment. Its portfolio centers on tumor-directed mono- and bispecific antibodies targeting the CD40 receptor and other immune pathways, including the lead candidate mitazalimab (a CD40 agonist for pancreatic cancer), the bispecific ATOR-4066 (CD40xCEACAM5), ALG.APV-527 (4-1BBx5T4), and ATOR-1017 (4-1BB agonist). The company also licenses the anti-HER2 antibody HLX22 via Shanghai Henlius, and offers proprietary bispecific platforms Neo-X-Prime and RUBY for partnership-based development.

Is Alligator Bioscience a public or private company?

Alligator Bioscience is a public company. It is classified as public and is currently operating.

When was Alligator Bioscience founded?

Alligator Bioscience was founded in 1997. It employs 11 to 50 people.

Where is Alligator Bioscience based?

Alligator Bioscience is headquartered in Lund, Sweden, in the Europe region.

Who are Alligator Bioscience's main competitors?

Direct peers on record are Aptevo Therapeutics, MacroGenics and Genmab. Emerging players are Bolt Biotherapeutics, Werewolf Therapeutics, CytomX Therapeutics, Compugen and Mereo BioPharma. Broad incumbents are Roche and AstraZeneca.

Does Alligator Bioscience have an API?

No public API is recorded for Alligator Bioscience.

What industry is Alligator Bioscience in?

Alligator Bioscience's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooNomination Committee Appointed in Respect of AGM 2027 in Alligator Bioscience ABAlligator Bioscience appointed its Nomination Committee for the AGM on 6 May 2027, consisting of three members representing about 3.28% of shares. The committee will prepare proposals for board and auditor elections, and shareholders may submit proposals until 31 January 2027.TradingViewNomination Committee appointed in respect of AGM 2027 in Alligator Bioscience ABAlligator Bioscience appointed its Nomination Committee for the AGM on 6 May 2027, consisting of three members representing about 3.28% of shares. The committee will prepare proposals for board and auditor elections, and shareholders may submit proposals by 31 January 2027.The future of tradingAlligator Bioscience agrees to sell mitazalimab to BiossilAlligator Bioscience agreed to sell worldwide rights to mitazalimab to Biossil for $750,000 upfront, with contingent milestones totaling up to $108 million. The seller retains mid-single-digit royalties capped at $250 million, and closing is expected within 30 days.The future of tradingAlligator Bioscience: Alligator Bioscience signs agreement to sell mitazalimab to BiossilAlligator Bioscience agreed to sell all rights to mitazalimab to Biossil, receiving $0.75 million upfront and up to $108 million in milestone payments plus royalties. Biossil will develop the drug, with closing expected within 30 days. The sale aligns with Alligator's strategy to focus on its HLX22 interest.TradingViewAlligator Bioscience signs agreement to sell mitazalimab to BiossilAlligator Bioscience signed an agreement to sell all rights to mitazalimab to Biossil, receiving $0.75 million upfront and up to $108 million in milestone payments plus royalties. The deal ends Alligator's mitazalimab development costs and supports its focus on HLX22.TradingViewAlligator Bioscience (ATORX) Sells Mitazalimab For $0.75M Upfront, Up To $108M MilestonesAlligator Bioscience agreed to sell all rights to mitazalimab to Biossil for $0.75 million upfront, with up to $108 million in milestones and mid-single-digit royalties capped at $250 million total. Closing is expected within 30 days, subject to conditions.The future of tradingAlligator Bioscience: Change in number of shares and votes in Alligator Bioscience ABAlligator Bioscience's rights issue, approved by the board on 23 July 2026 and the extraordinary general meeting on 26 August 2026, increased its share count. As of 30 October 2026, the company has 3,568,106,848 outstanding ordinary shares, each carrying one vote.TradingViewAlligator Bioscience AB (ATORX) Share Count Rises After Rights IssueAlligator Bioscience AB increased its outstanding shares to 3,568,106,848 after a rights issue of units approved on Aug. 26, 2026. The higher share count dilutes existing holders and affects per-share metrics. Proceeds usage and updated runway are expected catalysts.The future of tradingAlligator Bioscience proposes 1-for-1,000 reverse share splitAlligator Bioscience's board proposed a 1-for-1,000 reverse ordinary share split at its November 27, 2026, extraordinary general meeting. The split would raise quota value from SEK 0.005 to SEK 5, with split-adjusted trading scheduled for December 8, 2026. Shareholders will also vote on warrant issues and board elections.TradingViewATORX: HLX22 royalties anchor the refocused business, but cash runway and timing remain uncertainAlligator Bioscience is shifting operations to preserve HLX22 royalty potential, targeting cost reductions in Q2 2027. Phase III data are expected in H2 2027, while cash runway and royalties depend on wind-down obligations and clinical and commercial outcomes.